查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2110409

2026-2034年全球醫療保健製藥合約開發和生產組織（CDMO）市場規模、佔有率、趨勢和成長分析報告

Global Healthcare Contract Development and Manufacturing Organization Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 234 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球醫療保健藥品合約研發生產機構 (CDMO) 市場預計將從 2025 年的 3574.8 億美元成長至 2034 年的 1.0495 兆美元，並預計在 2026 年至 2034 年期間以 12.17% 的複合年成長率成長。隨著製藥和生技公司擴大將藥物研發和生產流程外包，全球 CDMO 市場正在快速擴張。 CDMO 提供廣泛的服務，包括藥物製劑開發、臨床試驗樣本生產和大規模生產。這種外包模式使企業能夠降低營運成本、提高效率並加速新療法的商業化。

CDMO市場的主要驅動力之一是藥物研發日益複雜化以及對專業化生產能力的需求不斷成長。製藥公司與CDMO合作，以利用現代藥物生產所需的先進技術和監管專業知識。此外，生物製藥和個人化醫療的進步也進一步推動了對專業化生產服務的需求。

隨著藥物研發管線的不斷擴展，CDMO市場預計將顯著成長。生物製造、連續生產製程和先進藥物遞送系統等領域的技術創新將提升產能。此外，隨著全球製藥公司在全球範圍內拓展生產夥伴關係關係，新興市場預計也將在市場成長中發揮重要作用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球醫療保健製藥合約開發與生產組織 (CDMO) 市場：按服務類型分類

  • 市場分析、洞察與預測
  • 合約開發（配方前開發、配方開發、製程開發和最佳化、分析、穩定性測試和分銷前測試）
  • 契約製造（原料藥生產、最終製劑、包裝及序列化服務、醫療設備）

第5章 全球醫療保健製藥合約開發與生產組織 (CDMO) 市場：按治療領域分類

  • 市場分析、洞察與預測
  • 腫瘤學
  • 心血管系統
  • 感染疾病
  • 神經病學/中樞神經系統（CNS）
  • 自體免疫/發炎性疾病
  • 代謝性疾病（糖尿病、肥胖症）
  • 罕見疾病/孤兒病
  • 其他

第6章 全球醫療保健藥品合約開發與生產組織（CDMO）市場：依開發階段分類

  • 市場分析、洞察與預測
  • 臨床前
  • 第一階段
  • 第二階段
  • 第三階段
  • 市場階段/核准後階段

第7章 全球醫療保健製藥合約開發與生產組織（CDMO）市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 大型製藥公司
  • 新興和虛擬生物技術公司
  • 學名藥生產商
  • 醫療設備和複合材料產品製造商
  • 學術機構、政府機構、非營利組織

第8章 全球醫療保健製藥合約開發和生產組織（CDMO）市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie Inc.（AbbVie Contract Manufacturing）
    • AGC Inc.（AGC Biologics）
    • CH Boehringer Sohn AG & Co. KG（Boehringer Ingelheim BioXcellence）
    • Cambrex Corporation
    • Delpharm SAS
    • Fareva SA
    • Flex Ltd.（Flex Health）
    • FUJIFILM Holdings Corporation（FUJIFILM Diosynth Biotechnologies）
    • Jabil Inc.（Jabil Healthcare）
    • Jubilant Pharmova Limited（Jubilant HollisterStier）
    • Lonza Group AG
    • Novo Holdings A/S（Catalent, Inc.）
    • PCI Pharma Services（PCI Services LLC）
    • Piramal Pharma Limited（Piramal Pharma Solutions）
    • Recipharm AB
    • Samsung Biologics Co.Ltd
    • Sanmina Corporation
    • Siegfried Holding AG
    • Simtra BioPharma Solutions（divested From Baxter International Inc.）
    • Thermo Fisher Scientific Inc.（Patheon）
    • Vetter Pharma-Fertigung GmbH & Co. KG
    • WuXi AppTec Co., Ltd.（WuXi STA/WuXi ATU）
簡介目錄
Product Code: VMR11216673

The global healthcare contract development and manufacturing organization market size is expected to reach USD 1004.95 Billion in 2034 from USD 357.48 Billion in 2025, growing at a CAGR of 12.17 during 2026-2034.The global healthcare contract development and manufacturing organization (CDMO) market is expanding rapidly as pharmaceutical and biotechnology companies increasingly outsource drug development and manufacturing processes. CDMOs provide a range of services, including drug formulation, clinical trial material production, and large-scale manufacturing. This outsourcing model helps companies reduce operational costs, improve efficiency, and accelerate the commercialization of new therapies.

One of the primary drivers of the CDMO market is the growing complexity of drug development and the increasing demand for specialized manufacturing capabilities. Pharmaceutical companies are collaborating with CDMOs to access advanced technologies and regulatory expertise required for modern drug production. Additionally, the rising development of biologics and personalized medicines is further driving the need for specialized manufacturing services.

In the future, the CDMO market is expected to grow significantly as pharmaceutical pipelines continue to expand. Technological innovations in biomanufacturing, continuous processing, and advanced drug delivery systems will enhance production capabilities. Emerging markets are also expected to play a crucial role in market growth as global pharmaceutical companies expand their manufacturing partnerships worldwide.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Service Type

  • Contract Development (Pre-formulation & Formulation Development, Process Development & Optimisation, Analytical, Stability & Release Testing)
  • Contract Manufacturing (API Manufacturing, Finished Dosage Formulation, Packaging & Serialization Services, Medical Devices)

By Therapeutic Area

  • Oncology
  • Cardiovascular
  • Infectious Diseases
  • Neurology / CNS
  • Auto-immune & Inflammatory
  • Metabolic Disorders (Diabetes, Obesity)
  • Rare & Orphan Diseases
  • Other Therapeutic Areas

By Development Phase

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Commercial / Post-Approval

By End User

  • Big / Large Pharmaceutical Companies
  • Emerging & Virtual Biotech Firms
  • Generic Drug Manufacturers
  • Medical-Device & Combination-Product Firms
  • Academic, Government & Non-Profit Sponsors

COMPANIES PROFILED

  • AbbVie Inc. (AbbVie Contract, Manufacturing), AGC Inc. (AGC Biologics), C.H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim BioXcellence), Cambrex Corporation, Delpharm SAS, Fareva S.A., Flex Ltd. (Flex Health), FUJIFILM Holdings Corporation (FUJIFILM Diosynth Biotechnologies), Jabil Inc. (Jabil Healthcare), Jubilant Pharmova Limited (Jubilant HollisterStier), Lonza Group AG, Novo Holdings A/S (Catalent, Inc.), PCI Pharma Services (PCI Services LLC), Piramal Pharma Limited (Piramal Pharma Solutions), Recipharm AB, Samsung Biologics Co., Ltd., Sanmina Corporation, Siegfried Holding AG, Simtra BioPharma Solutions (divested from Baxter International Inc.), Thermo Fisher Scientific Inc. (Patheon), Vetter Pharma-Fertigung GmbH & Co. KG, WuXi AppTec Co., Ltd. (WuXi STA / WuXi ATU)

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Service Type
  • 4.2. Contract Development (Pre-formulation & Formulation Development, Process Development & Optimisation, Analytical, Stability & Release Testing) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Contract Manufacturing (API Manufacturing, Finished Dosage Formulation, Packaging & Serialization Services, Medical Devices) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Therapeutic Area
  • 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Neurology / CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Auto-immune & Inflammatory Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Metabolic Disorders (Diabetes, Obesity) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Rare & Orphan Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.9. Other Therapeutic Areas Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY DEVELOPMENT PHASE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Development Phase
  • 6.2. Pre-clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Phase I Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Phase II Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Phase III Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Commercial / Post-Approval Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY END USER 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End User
  • 7.2. Big / Large Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Emerging & Virtual Biotech Firms Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Generic Drug Manufacturers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Medical-Device & Combination-Product Firms Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.6. Academic, Government & Non-Profit Sponsors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Service Type
    • 8.2.2 By Therapeutic Area
    • 8.2.3 By Development Phase
    • 8.2.4 By End User
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Service Type
    • 8.3.2 By Therapeutic Area
    • 8.3.3 By Development Phase
    • 8.3.4 By End User
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Service Type
    • 8.4.2 By Therapeutic Area
    • 8.4.3 By Development Phase
    • 8.4.4 By End User
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Service Type
    • 8.5.2 By Therapeutic Area
    • 8.5.3 By Development Phase
    • 8.5.4 By End User
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Service Type
    • 8.6.2 By Therapeutic Area
    • 8.6.3 By Development Phase
    • 8.6.4 By End User
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL HEALTHCARE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AbbVie Inc. (AbbVie Contract Manufacturing)
    • 10.2.2 AGC Inc. (AGC Biologics)
    • 10.2.3 C.H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim BioXcellence)
    • 10.2.4 Cambrex Corporation
    • 10.2.5 Delpharm SAS
    • 10.2.6 Fareva S.A
    • 10.2.7 Flex Ltd. (Flex Health)
    • 10.2.8 FUJIFILM Holdings Corporation (FUJIFILM Diosynth Biotechnologies)
    • 10.2.9 Jabil Inc. (Jabil Healthcare)
    • 10.2.10 Jubilant Pharmova Limited (Jubilant HollisterStier)
    • 10.2.11 Lonza Group AG
    • 10.2.12 Novo Holdings A/S (Catalent, Inc.)
    • 10.2.13 PCI Pharma Services (PCI Services LLC)
    • 10.2.14 Piramal Pharma Limited (Piramal Pharma Solutions)
    • 10.2.15 Recipharm AB
    • 10.2.16 Samsung Biologics Co.Ltd
    • 10.2.17 Sanmina Corporation
    • 10.2.18 Siegfried Holding AG
    • 10.2.19 Simtra BioPharma Solutions (divested From Baxter International Inc.)
    • 10.2.20 Thermo Fisher Scientific Inc. (Patheon)
    • 10.2.21 Vetter Pharma-Fertigung GmbH & Co. KG
    • 10.2.22 WuXi AppTec Co., Ltd. (WuXi STA / WuXi ATU)